TITLE

GENEREX BIOTECHNOLOGY AWARDED NEW DRUG DELIVERY PATENT

PUB. DATE
December 2008
SOURCE
Worldwide Biotech;Dec2008, Vol. 20 Issue 12, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
35409952

 

Related Articles

  • GENEREX AWARDED TWO NEW PATENTS FOR BUCCAL DRUG DELIVERY.  // Biotech Business;Jul2010, Vol. 23 Issue 7, p7 

    The article reports that Generex Biotechnology Corporation was awarded patents in Japan and Ukraine. According to Rose C. Perri, the company's chief operating officer, each patent issuance suggests the inventiveness of the company's buccal drug delivery platform technologies. Generex is based in...

  • European patents for Generex.  // European Pharmaceutical Executive;Sep2007, p9 

    The article reports that the European Patent Office has granted the fourth European patent of Generex Biotechnology Corp. entitled "Proteinic Drug Delivery System Using Membrane Mimetics." The patent includes formulation and process claims for liposome pharmaceutical formulation, which was...

  • Generex Biotechnology: vaccines a clear way ahead for RapidMist.  // PharmaWatch: Biotechnology;September 2004, Vol. 3 Issue 9, p6 

    Reports on the innovation made by Generex Biotechnology Corp. for the RapidMist platform technology for vaccine delivery. Uncertain profitability of the delivery system; Discussion of the prospects for Generex's RapidMist delivery system during the Foundation Merieux Conference in 2004.

  • GENEREX AWARDED PATENTS IN NORTH AND SOUTH AMERICA.  // Worldwide Biotech;Apr2008, Vol. 20 Issue 4, p7 

    The article announces that Generex Biotechnology Corp. has received patents in Canada and Argentina. The Canadian Intellectual Property Office has granted Generex a patent that contains process, formulation and use claims to a mixed micellar pharmaceutical formulation for buccal administration,...

  • GENEREX GETS CHINA PATENT FOR II-KEY PETIDE VACCINE.  // Worldwide Biotech;Apr2010, Vol. 22 Issue 4, p1 

    The article reports that Generex Biotechnology Corp. has received a patent for its Ii-Key peptide vaccine technology in China. The company has begun discussions for potential joint venture/licensing partnerships with pharmaceutical companies for its peptide cancer vaccine technology platform....

  • Generex Biotech receives new patents for buccal applications.  // Medical Device Daily;6/15/2009, Vol. 13 Issue 113, p10 

    The article reports on the five patents in Canada, Australia, New Zealand, Brazil and Lebanon received by Generex Biotechnology. Additional protection for Generex's proprietary compositions and methodologies for delivering pharmaceuticals in buccal applications is provided by the patents. It is...

  • Generex Biotechnology: vaccines a clear way ahead for RapidMist.  // PharmaWatch: Monthly Review;September 2004, Vol. 3 Issue 9, p50 

    Reports on chief scientific officer of Generex Biotechnology's Antigen Express immunomedicines subsidiary, Robert Humphreys' presentation of a research abstract at the Foundation Merieux Conference discussing the prospects for the company's RapidMist delivery system. Benefits of the technology...

  • Gum to replace needles?  // Pharmaceutical Technology Europe;Feb2006, Vol. 18 Issue 2, p10 

    The article reports on Generex's development of a chewing gum as an alternative buccal drug delivery method for metformin, which is used for treating diabetes. Results from a small clinical trial suggest that the use of chewing gum could prevent gastrointestinal side-effects which usually...

  • Insulin spray will eliminate needles.  // Hudson Valley Business Journal;09/25/2000-10/09/2000, Vol. 11 Issue 16, p14 

    Reports that Eli Lilly and Co. has signed an agreement with Generex Biotechnology Corp. to develop insulin that is administered as a fine spray into the mouth.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics